FDA Inspection
Megafine Pharma (P) LimitedMegafine Pharma (P) Limited – FDA Inspection, Mar 6, 2020
Record Details
This FDA Inspection record concerns Megafine Pharma (P) Limited, with an inspection on March 6, 2020, issued by the Center for Drug Evaluation and Research, covering drugs.
- Company
- Megafine Pharma (P) Limited
- Inspection Date
- March 6, 2020
- Product Type
- Drugs
View Company Profile
ID · d31b8c30-3b1a-4524-8262-69f74885e8e4
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1122874
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
Other FDA inspections of Megafine Pharma (P) Limited
4| Date | Classification | Office | Project area |
|---|---|---|---|
| January 24, 2023 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 12, 2018 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 15, 2015 | OAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 2, 2011 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Megafine Pharma (P) Limited
- FDA Inspection 1195646 - 2023-01-24
- FDA Inspection 1054711 - 2018-05-12
- FDA Inspection 929021 - 2015-05-15
- FDA Inspection 730085 - 2011-06-02
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.